Age, Biography and Wiki

Ze'ev Ronai was born on 1956, is an An israeli medical researchers. Discover Ze'ev Ronai's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 68 years old?

Popular As N/A
Occupation N/A
Age 68 years old
Zodiac Sign N/A
Born 1956
Birthday
Birthplace N/A
Nationality

We recommend you to check the complete list of Famous People born on . He is a member of famous with the age 68 years old group.

Ze'ev Ronai Height, Weight & Measurements

At 68 years old, Ze'ev Ronai height not available right now. We will update Ze'ev Ronai's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Ze'ev Ronai Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Ze'ev Ronai worth at the age of 68 years old? Ze'ev Ronai’s income source is mostly from being a successful . He is from . We have estimated Ze'ev Ronai's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income

Ze'ev Ronai Social Network

Instagram
Linkedin
Twitter
Facebook
Wikipedia
Imdb

Timeline

Ze’ev Ronai is an Israeli-American cancer research scientist and Chief Scientific Advisor at the Sanford Burnham Prebys Medical Discovery Institute in La Jolla.

1956

Ze’ev Ronai was born in Haifa in 1956.

He attended Hugim High School in Haifa, and received his B.S. (Biology) and Ph.D. (Immunology) from the Hebrew University of Jerusalem.

Ronai's studies provide new fundamental understanding for the role and function of epigenetic components (transcription factor and ubiquitin ligases) in cancer.

Early in his career he developed a sensitive PCR approach to detect mutant Ras oncogene in normal appearing tissues.

Later on, his studies provided the foundation for the rewired signaling in cancer, by demonstrating the important role of protein subcellular localization in its oncogenic function and by establishing the function of ubiquitin ligases in key cellular processes (i.e. hypoxia, unfolded protein response, mitochondrial dynamics, anti-tumor immunity ) and their critical contribution to development, progression, and therapy resistance of prostate and breast cancers and melanoma.

He developed SBI-756, a small molecule inhibitor, which targets the translation initiation complex, inhibiting melanoma and lymphoid tumors.

Ze’ev Ronai published close to 300 peer-reviewed publications, reflected in over 20,000 citations.

Following post doctoral training with I.B. Weinstein at Columbia University, Ronai began his independent career on the campus of the New York Medical College, followed by tenure at Mount Sinai School of Medicine in NY.

He also served as SBP's Scientific Director.

In Israel, he has established the Technion Integrated Cancer Center, (with the Nobel Laureate Aaron Ciechanover), first in class where engineers biologists and oncologists collaborate to defeat cancer.

1980

Ze’ev Ronai is married to Iris Ronai (1980); they have three children.

1996

Ronai obtained a number patents for his inventions; those include a "Quantitative method for early detection of mutant alleles and diagnostic kits for carrying out the method" (1996), "Inhibition of ATF2 activity to treat cancer" (2011), and "Compositions and methods for inhibiting growth and metastasis of melanoma" (2011).

2016

Ronai received the Lifetime Achievement Award from the Society for Melanoma Research (2016).

Earlier, he obtained the Golda Meir Fellowship from the Hebrew University.

He also served as editor in chief of Pigment Cell & Melanoma Research.